About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT07035678

A Study on the Associations of Toll-like Receptor 5 Gene Polymorphisms With Crohn's Disease in Chinese Patients

The exact etiology and pathogenesis of Crohn's disease (CD) have not been fully elucidated, and may be related to the combined effects of genetics, environment, immunity, gut microbiota, and many othe...

Lead sponsor: Second Affiliated Hospital of Wenzhou Medical University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. After receiving IFX conventional treatment plan for 30 weeks;
•2. Not participated in any other experimental projects in the past three months;
•3. There are no other serious and life-threatening diseases in various systems.

Exclusion Criteria

•1. Pregnancy;
•2. Breastfeeding;
•3. Severe drug allergy (having experienced severe drug allergic reactions such as anaphylactic shock, systemic dermatitis, etc.);
•4. Merge with other autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis);
•5. Merge malignant tumors;
•6. Serious cardiovascular and cerebrovascular diseases;
•7. Poor patient compliance or presence of mental disorders;
•8. Incomplete case data.

Related studies

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

RECRUITINGPhase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931 · Crohn's Disease

RECRUITINGPhase 2

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808 · Perianal Fistula Due to Crohn's Disease

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

NCT06647615 · Crohn's Disease, Abdominal Pain (AP)

Pregnancy and Inflammatory Bowel Disease

NCT07377188 · IBD, Crohn's Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 25, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment825

Start dateJan 2019

Last updatedJun 25, 2025

Condition

Crohn's Disease Ustekinumab Toll-like Receptor 5 Polymorphism, Single Nucleotide

Locations shown

Second Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 25, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions